# Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome

Source: https://onco.cc/trials/nct02521493/  
OnCo record `nct02521493` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Asparaginase, Crisantaspase, Cytarabine, Daunorubicin, Etoposide, Mitoxantrone and Thioguanine in Acute myeloid leukaemia and Leukaemia, run by Children's Oncology Group, active and no longer recruiting.

## Summary

Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome is a phase 3 interventional study registered as NCT02521493 by Children's Oncology Group, with 280 participants planned, started 2015-12-23 and due to reach its primary completion in 2024-06-30. Interventions recorded: Asparaginase, Asparaginase Erwinia chrysanthemi, Cytarabine, Daunorubicin Hydrochloride, Etoposide, Laboratory Biomarker Analysis, Mitoxantrone Hydrochloride, Thioguanine. Conditions recorded: Acute Myeloid Leukemia, Down Syndrome, Myelodysplastic Syndrome, Myeloid Leukemia Associated With Down Syndrome, Myeloproliferative Neoplasm.

Linked to the drug Crisantaspase because the registry names it among its interventions and Acute myeloid leukaemia and Leukaemia among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT02521493
- Phase: 3
- Setting: Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
- Sponsor: Children's Oncology Group
- Enrolled: 280

## Sources

- ClinicalTrials.gov NCT02521493: https://clinicaltrials.gov/study/NCT02521493

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [Leukaemia (all types)](https://onco.cc/cancers/leukaemia/)
- drugs: [Asparaginase (pegaspargase, calaspargase pegol, Erwinia asparaginase)](https://onco.cc/drugs/asparaginase/), [Crisantaspase (recombinant Erwinia asparaginase)](https://onco.cc/drugs/crisantaspase/), [Cytarabine](https://onco.cc/drugs/cytarabine/), [Daunorubicin](https://onco.cc/drugs/daunorubicin/), [Etoposide](https://onco.cc/drugs/etoposide/), [Mitoxantrone](https://onco.cc/drugs/mitoxantrone/), [Thioguanine](https://onco.cc/drugs/thioguanine/)

---
JSON: https://onco.cc/api/v1/entities/nct02521493.json